Reuters logo
in 10 months
BRIEF-Syros announces approval of Investigational Device Exemption (IDE) for blood test to identify cancer patients with proprietary biomarkers
October 11, 2016 / 12:11 PM / in 10 months

BRIEF-Syros announces approval of Investigational Device Exemption (IDE) for blood test to identify cancer patients with proprietary biomarkers

1 Min Read

Oct 11 (Reuters) - Syros Pharmaceuticals Inc

* Syros announces approval of investigational device exemption (IDE) for blood test to identify cancer patients with proprietary biomarkers

* Syros Pharmaceuticals-approval of IDE allows Co to expand phase 2 clinical trial to include newly diagnosed AML patients 60 years of age or older Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below